HER2 in endometrioid endometrial adenocarcinoma (E-EMCA): defining incidence, molecular profiles, and outcomes | Caris Life Sciences
Portal
Order
Home / Research / Publications / HER2 in endometrioid endometrial adenocarcinoma (E-EMCA): defining incidence, molecular profiles, and outcomes

Publications

Back

HER2 in endometrioid endometrial adenocarcinoma (E-EMCA): defining incidence, molecular profiles, and outcomes

– Caris Life Sciences

Poster

Key Finding:

5% of endometrioid endometrial adenocarcinomas are HER2+, as assessed by ERBB2 expression, and have a hot immune phenotype. 

Download Publication

Discover
More

  • Spliceosome Mutations in Metastatic Breast Cancer An Analysis of a Decentralized Clinical Trial and Large Clinical Genomic Dataset

    – Caris Life Sciences

    Poster

    […]

  • Molecular landscape of HR+/HER2- male breast cancer (MaBC) compared with female breast cancer (FeBC)

    – Caris Life Sciences

    Poster

    […]
Learn More

Ready to Get Started on the Journey?

Name(Required)